Pipelines

© GettyImages/Martin Barraud

4D Pharma sees positive data from early stage asthma trial

By Jane Byrne

Live biotherapeutic product (LBP) developer, 4D Pharma, which has been NASDAQ listed since March this year, has announced positive topline results for the first part of its Phase I/II trial of an LBP strain for the treatment of asthma.

© GettyImages/Monty Rakusen

Lonza and Doer Biologics in expression system license deal

By Jane Byrne

Lonza has signed a licensing agreement with clinical-stage biopharma, Zhejiang Doer Biologics, whereby the Hangzhou, China based biopharma company will develop multi-specific biotherapeutics using the Swiss CDMO’s XS Pichia.

© GettyImages/PonyWang

Sphere Fluidics closes $40m funding round

By Jane Byrne

Sphere Fluidics, a UK company that has developed and is commercializing single cell analysis systems underpinned by its picodroplet technology, has just closed a US$40m investment round.

© GettyImages/courtneyk

Thermo Fisher opens Swiss biologics production facility

By Jane Byrne

The operation of the 1.5 million square-foot biologics manufacturing site in Lengnau, Switzerland is part of a strategic partnership agreed with CSL Limited, announced last year, says Thermo Fisher Scientific.

© GettyImages/Design Cells

AstraZeneca invests in saRNA specialist

By Jane Byrne

AstraZeneca has announced a long-term research collaboration with VaxEquity for the discovery, development and commercialization of its self-amplifying RNA (saRNA) therapeutics platform.

Follow us

Webinars